IP Library Granted Patent US 10,363,297
Granted Patent B2
US 10,363,297 · App. 14/949,291 · Granted Jul 30, 2019

Immunogenic compositions containing

Inventors: David Gally (Edinburgh, GB); Tom Nathan McNeilly (Midlothian, GB); David George Emslie Smith (Midlothian, GB); Chris Low (Midlothian, GB); Arvind Kumar Mahajan (Edinburgh, GB); Stuart W. Naylor (Edinburgh, GB)
Assignees: The University Court of the University of Edinburgh; Moredun Research Institute; SRUC
A61K39/0258A61K39/39C07K14/245C07K16/1232A61K39/00A61K2039/552A61K2039/55555A61K2039/55577A61K2039/57C07K2319/00Y02A50/474
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,363,297
App. No.
14/949,291
Granted
Jul 30, 2019
Kind
B2
Abstract

Immunogenic compositions containing Escherichia coli 0157:H7 flagella including fusion proteins and methods using the immunogenic compositions are disclosed. Inducing an immune response in an animal to Escherichia coli O157:H7 flagella will result in prevention of colonization by Escherichia coli O157:H7 in the animal or a reduction in the amount of Escherichia coli O157:H7 infecting the animal. The immune composition will prevent or reduce the attachment of Escherichia coli 0157:H7 to cells within the animal.

Claims (8)

1. A method for generating a mucosal and/or IgA response in a subject in need thereof, said method comprising the parenteral administration of Escherichia coli H7 or a Toll-like receptor 5 (TLR5) activating fragment thereof.

2. The method of claim 1 , wherein the subject is an agricultural animal.

3. The method of claim 2 , wherein the agricultural animal is a ruminant animal.

4. The method of claim 1 , wherein the H7 or TLR5 activating fragment thereof is derived from Escherichia coli O157:H7.

5. The method of claim 1 , wherein the H7 or TLR5 activating fragment thereof comprises an amino acid sequence at least 97% homologous to SEQ ID NO: 2.

6. The method of claim 1 , wherein the H7 or TLR5 activating fragment thereof comprises the amino acid sequence of SEQ ID NO: 2.

7. The method of claim 1 , wherein the H7 or TLR5 activating fragment thereof is encoded by the nucleic acid sequence of SEQ ID NO: 1.

8. The method of claim 1 , wherein the method further comprises administering an adjuvant.

Assignments (2)
CHANGE OF NAME Recorded Apr 6, 2016
From: THE SCOTTISH AGRICULTURAL COLLEGE
To: SRUC
Reel/Frame 038364/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2016
From: GALLY, DAVID; MCNEILLY, TOM NATHAN; SMITH, DAVID GEORGE EMSLIE; LOW, CHRIS; MAHAJAN, ARVIND KUMAR; NAYLOR, STUART W.
To: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH; MOREDUN RESEARCH INSTITUTE; THE SCOTTISH AGRICULTURAL COLLEGE
Reel/Frame 038190/0327 →
Priority Claims (1)
GB 0720250.0 · Oct 17, 2007 · national
Continuity (2)
Division 12738627
Related Publication 20160074493A1 · Mar 17, 2016